Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19.56% stake in the company

share with twitter share with LinkedIn share with facebook
10/18/2019 | 01:05am EDT

Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19.56% stake in the company

Dublin, Ireland - October 18, 2019 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that it has concluded a licensing agreement for Aemcolo™ for the USA and a simultaneous share subscription agreement with RedHill Biopharma (NASDAQ: RDHL, Tel-Aviv Stock Exchange: RDHL).

Aemcolo™ is Cosmo's recently FDA approved antibiotic for the treatment of Travelers' Diarrhea and is also in Phase II clinical trials for IBS-D.

RedHill Biopharma is focused on the development and commercialization of clinical late-stage drugs for the treatment of gastrointestinal diseases. RedHill already commercializes gastrointestinal products in the U.S. and currently has a sales force of approximately 40 sales representatives, which it plans to further expand to approximately 140 sales representatives assuming approval of its drug RHB-105 (Talicia) for the treatment of H. pylori infection. RHB-105's PDUFA date is set for November 2, 2019.

The license agreement provides for high twenty percent royalties and potential regulatory and commercial cash milestones totalling up to USD 100m, plus a USD 12m down-payment in RedHill ADSs (American Depositary Shares listed on NASDAQ). Cosmo will be the exclusive supplier of Aemcolo™.

The share subscription agreement provides for an investment of USD 36.3m in RedHill ADSs at a price equal to the last 30-day average. Together with the ADSs received as down-payment, Cosmo will hold an overall stake in the company of 19.56% and will become the largest shareholder in RedHill. Cosmo will be entitled to appoint one board member of RedHill.

Mauro Ajani, Chairman of Cosmo, said: "This deal is another big step in the transformation of Cosmo and it is closer to our history. After the deals with Medtronic, where we partnered AI and Eleview, we have now found the right US partner for Aemcolo™. We are most pleased to become RedHill's largest shareholder: this stake is strategic and a demonstration of trust. We look forward to contributing towards making RedHill a rousing success."

Alessandro Della Chà, CEO of Cosmo, said: "After having received several offers, we believe we have found in RedHill the features for a long and successful collaboration: a strong and expert management team with a history of commercial success, a very interesting pipeline, a company size where our contribution could make a substantial difference and the opportunity of an equity for product deal. We are very happy to start this new partnership".

"Cosmo is a world leader in optimized therapies for gastrointestinal diseases with a strong track record of success, expertise and commitment to changing the treatment landscape for patients", said Dror Ben-Asher, RedHill's CEO. "The strategic partnership with Cosmo is an important validation of RedHill's commercial capabilities, promising late-stage pipeline and overall strategy to become a leading gastrointestinal-focused company in the US. Cosmo's investment in RedHill ahead of the potential FDA approval and if approved by the FDA, the launch of RHB-105 (Talicia) and the addition of Aemcolo® to our GI product portfolio positions us well for the future. We are proud to have Cosmo as our partner and look forward to a successful strategic collaboration."




Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50

share with twitter share with LinkedIn share with facebook
All news about COSMO PHARMACEUTICALS N.V.
10/12COSMO PHARMACEUTICALS N : Acacia Pharma completes drawdown from EUR25 million lo..
AQ
08/28COSMO PHARMACEUTICALS N : announces FDA Approval for Cassiopea's Winlevi, First-..
AQ
08/27Cassiopea gets U.S. FDA approval for acne treatment Winlevi
RE
08/27COSMO PHARMACEUTICALS N : announces FDA Approval for Cassiopea's Winlevi ® (clas..
PU
08/27Cosmo Pharmaceuticals announces FDA Approval for Cassiopea's Winlevi® (clasco..
TE
08/24COSMO PHARMACEUTICALS N : NV - Methylene Blue MMX approved in Europe for the vis..
AQ
08/21Methylene Blue MMX approved in Europe for the visualization of colorectal les..
TE
08/13REDHILL BIOPHARMA : and Cosmo Pharmaceuticals to Expand Strategic Partnership wi..
AQ
08/13Cosmo and RedHill Biopharma to Expand Strategic Partnership with Exclusive Li..
TE
07/30Cosmo Half-Year Report 2020
TE
More news
Financials
Sales 2020 52,6 M 62,0 M 62,0 M
Net income 2020 -8,55 M -10,1 M -10,1 M
Net cash 2020 37,3 M 43,9 M 43,9 M
P/E ratio 2020 -119x
Yield 2020 -
Capitalization 1 147 M 1 351 M 1 350 M
EV / Sales 2020 21,1x
EV / Sales 2021 17,7x
Nbr of Employees 261
Free-Float 45,8%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 93,85 €
Last Close Price 79,28 €
Spread / Highest target 40,4%
Spread / Average Target 18,4%
Spread / Lowest Target -15,1%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.12.39%1 362
JOHNSON & JOHNSON-1.06%389 921
ROCHE HOLDING AG-0.56%291 357
PFIZER INC.-3.14%210 884
MERCK & CO., INC.-13.50%201 909
NOVARTIS AG-14.09%190 074